Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MacroGenics, Inc. - Common Stock (NQ:MGNX)

2.200 -0.090 (-3.93%)
Delayed Quote Updated: 4:00 PM EST, Nov 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MacroGenics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
From MacroGenics, Inc.
Via GlobeNewswire
Top US Stock Gainers and Losers in Today's Session ↗
Via Chartmill
MacroGenics (NASDAQ:MGNX): A Minervini Trend Template High-Growth Momentum Case Study ↗
Via Chartmill
Today's U.S. Session Top Movers: Small-Cap Gainers and Losers ↗
Via Chartmill
Gap-Up and Gap-Down Stocks: October 23, 2026 Session ↗
Via Chartmill
News headline image
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited. ↗
The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs. 
Via The Motley Fool
News headline image
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations
TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced... 
Via MediaOutReach
Topics Economy
News headline image
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Eyes $200M Cash Boost, 2028 Runway Ahead of Cancer Pipeline Updates ↗
MacroGenics (NASDAQ:MGNX) Chief Executive Officer Eric Risser said the biotechnology company has strengthened its balance sheet through two recent transactions while preparing for a series of clinical... 
Via MarketBeat
News headline image
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
From MacroGenics, Inc.
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million 
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies ↗
Barclays increased the price target on the stock to $4 from $3 and kept an ‘Overweight’ rating on the shares. 
Via Stocktwits
Which stocks are moving on Tuesday? ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer 
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
What's going on in today's after hours session ↗
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.